Diabetes herbals recalled
This article was originally published in The Tan Sheet
Executive Summary
Two California firms announce March 23 they have initiated recalls of herbal supplements containing a prescription drug used to treat diabetes. SciQuest Lab's Dimelstat and Diabetic Capital's Dianolyn Capsules contain glyburide, a blood sugar-lowering medication that could cause "life-threatening complications" for diabetes patients, the companies acknowledge. Dianolyn is manufactured in China and then packaged and distributed in the U.S., Diabetic Capital explains. In February, the California Department of Health Services' Food & Drug Branch and FDA prompted a recall of two other supplements that contained glyburide and phenformin (1"The Tan Sheet" Feb. 21, p. 9)
You may also be interested in...
Five Chinese Herbals Contain Drug Ingredients, Calif. Health Dept. Warns
The California Department of Health Services' Food & Drug branch posted a public health warning Feb. 15 notifying consumers that five Chinese herbal products contain the prescription diabetes drugs glyburide and phenformin.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands